• UAW drops unfair labor practice lawsuits against General Motors and Stellantis
  • BAE Systems wins £4 billion UK contract for AUKUS submarine program.
  • UBS agrees to settle Credit Suisse's Mozambique litigation. The Swiss bank also states that it is "not aware" of the US investigation into breaches of compliance with sanctions against Russia.
  • Apple identifies iPhone 15 overheating problems.
  • BASF plans to sell around ten billion euros of assets.
  • Silver Lake and partner take 87% stake in Software AG following public tender offer.
  • BaFin will send special auditor to Deutsche Bank, due to concerns at PostBank, according to Handelsblatt.
  • BP Plc announces the departure of its US operations director, Dave Lawler, replaced by Orlando Alvarez.
  • Novartis finalized the sale of its ophthalmology assets to Bausch + Lomb for up to $2.5 billion.
  • Ascential confirms exclusive discussions with Apax on a possible sale of WGSN.
  • Two groups, including Apollo, acquire SAS AB, according to Aftenposten.
  • Vestas wins 76 MW order in Italy.
  • Axel Springer has not officially launched a bidding procedure for the British newspapers Daily Telegraph and Sunday Telegraph, according to Reuters, despite rumors.
  • Uniper will repay €2 billion in state aid this week.
  • Walmart announced on Saturday that it would be streamlining job titles within its workforce, in some cases accompanied by pay rises.
  • European competition authorities have not opened a formal investigation into chips used for artificial intelligence, the European Commission said on Monday, following raids in France targeting Nvidia for possible anti-competitive practices.
  • Viatris - On Sunday, the pharmaceutical company announced agreements to divest some of its activities for a total of up to $3.6 billion, as part of its long-term strategy to focus on three therapeutic areas.
  • MGM - Employees at three Detroit casinos, including one owned by MGM, voted to authorize a strike, if necessary, the United Auto Workers (UAW) and Teamsters announced on Saturday.
  • Eli Lilly - The US Food and Drug Administration has refused to approve the group's drug to treat a type of skin disease.